40900 Tralokinumab modulates the transcriptomic profile of lesional and non-lesional skin in adolescents with moderate-to-severe atopic dermatitis assessed by tape-stripping
Pavel A, Simpson E, Soong W, Antaya R, Imafuku S, Pilger S, Litman T, Røpke M, Arlert P, Yassky E. 40900 Tralokinumab modulates the transcriptomic profile of lesional and non-lesional skin in adolescents with moderate-to-severe atopic dermatitis assessed by tape-stripping. Journal Of The American Academy Of Dermatology 2023, 89: ab241. DOI: 10.1016/j.jaad.2023.07.963.Peer-Reviewed Original ResearchSevere atopic dermatitisNon-lesional skinAtopic dermatitisTranscriptomic profilesTralokinumabDermatitis